Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis - NCT04982289

Adverse Events (AEs) And Serious Adverse Events (SAEs) Up To Week 24, AEs And SAEs Up To Week 82, Change From Baseline In Serum Total Immunoglobulin G (IgG), (and 9 more...)